Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Harper

Showing results (511-520 of 522) with videos related to

Pageof 53
Sort By:
Cancer Research|November 21, 2022
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell StatesLaura E Stevens, Guillermo Peluffo, Xintao Qiu, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2011
Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1)Shung C Wu, David Yoon, Janice Chin, et al.
Journal of Medicinal Chemistry|October 28, 2017
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)Donald J P Pinto, Michael J Orwat, Leon M Smith, et al.
Journal of Medicinal Chemistry|December 14, 2019
Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 GroupsJames R Corte, Donald J P Pinto, Tianan Fang, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2001
BMS-196085: a potent and selective full agonist of the human beta(3) adrenergic receptorA V Gavai, P M Sher, A B Mikkilineni, et al.
Clinical Pharmacology and Therapeutics|April 12, 2017
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug PrescribingP H O'Donnell, N Wadhwa, K Danahey, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
BMS-201620: a selective beta 3 agonistW N Washburn, C-Q Sun, G Bisacchi, et al.
Cell Reports|December 15, 2023
Heterogeneity and transcriptional drivers of triple-negative breast cancerBojana Jovanović, Daniel Temko, Laura E Stevens, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2001
Beta 3 agonists. Part 1: evolution from inception to BMS-194449W N Washburn, P M Sher, K M Poss, et al.
Journal of Medicinal Chemistry|May 25, 2017
Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 InhibitorXiang-Yang Ye, Stephanie Y Chen, Shung Wu, et al.
Pageof 53

Showing results (511-520 of 522) with videos related to

Sort By:
Pageof 53
Cancer Research|November 21, 2022
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell StatesLaura E Stevens, Guillermo Peluffo, Xintao Qiu, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2011
Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1)Shung C Wu, David Yoon, Janice Chin, et al.
Journal of Medicinal Chemistry|October 28, 2017
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)Donald J P Pinto, Michael J Orwat, Leon M Smith, et al.
Journal of Medicinal Chemistry|December 14, 2019
Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 GroupsJames R Corte, Donald J P Pinto, Tianan Fang, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2001
BMS-196085: a potent and selective full agonist of the human beta(3) adrenergic receptorA V Gavai, P M Sher, A B Mikkilineni, et al.
Clinical Pharmacology and Therapeutics|April 12, 2017
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug PrescribingP H O'Donnell, N Wadhwa, K Danahey, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
BMS-201620: a selective beta 3 agonistW N Washburn, C-Q Sun, G Bisacchi, et al.
Cell Reports|December 15, 2023
Heterogeneity and transcriptional drivers of triple-negative breast cancerBojana Jovanović, Daniel Temko, Laura E Stevens, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2001
Beta 3 agonists. Part 1: evolution from inception to BMS-194449W N Washburn, P M Sher, K M Poss, et al.
Journal of Medicinal Chemistry|May 25, 2017
Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 InhibitorXiang-Yang Ye, Stephanie Y Chen, Shung Wu, et al.
Pageof 53